The Experts below are selected from a list of 203484 Experts worldwide ranked by ideXlab platform
Edoardo G Giannini - One of the best experts on this subject based on the ideXlab platform.
-
external validation of the platelet count spleen diameter ratio for the diagnosis of esophageal varices in hepatitis c virus related cirrhosis
Digestive Diseases and Sciences, 2009Co-Authors: Adnan Agha, Eram Anwar, Kaukab Bashir, Vincenzo Savarino, Edoardo G GianniniAbstract:Background Screening for esophageal varices (EV) is an important part of the diagnostic workup of cirrhotic patients. Aims To independently validate the use of the platelet count/spleen diameter ratio for the non-invasive diagnosis of EV in patients with HCV-related cirrhosis and in a sub-group of patients with compensated disease. Methods A platelet count/spleen diameter ratio cut-off value of 909 was evaluated for the diagnosis of EV in the whole population (n = 311) and in patients with compensated disease alone (n = 114). Compensated disease was defined as the absence of ascites as detected by abdominal ultrasound in patients who are not on diuretics and absence of hepatic encephalopathy. Results In the whole cohort (EV prevalence 49.5%), the platelet count/spleen diameter ratio 909 cut-off value had 96.9% positive predictive value, 100% negative predictive value, and 98.4% efficiency for EV diagnosis. In compensated cirrhotics (EV prevalence 26.3%), the platelet count/spleen diameter ratio 909 cut-off showed an excellent negative predictive value (100%) and a positive predictive value of 93.8%. for the diagnosis of EV. Conclusions In patients with HCV-related cirrhosis, the platelet count/spleen diameter may be proposed as a non-invasive tool for EV diagnosis, especially in financially deprived developing countries.
-
application of the platelet count spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis a validation study based on follow up
Digestive and Liver Disease, 2005Co-Authors: Edoardo G Giannini, Vincenzo Savarino, Federica Botta, P Borro, Pietro Dulbecco, Emanuela Testa, C Mansi, R TestaAbstract:Abstract Background. Screening for oesophageal varices represents an important part of the diagnostic work-up of cirrhotic patients. We have previously shown that the platelet count/spleen diameter ratio is a parameter that can rule out the presence of oesophageal varices safely and in a cost-effective fashion. Aim. To evaluate the prognostic and diagnostic accuracy of the platelet count/spleen diameter ratio for ruling out the presence of oesophageal varices in the follow-up of a cohort of cirrhotic patients without oesophageal varices at inclusion. Methods. After initial endoscopy, the 106 cirrhotic patients without oesophageal varices who participated in our previous study were followed-up with annual or biannual surveillance endoscopy. Patients were censored at the time of diagnosis of oesophageal varices or at their last visit, and at that time platelet count and spleen diameter were recorded. Sixty-eight patients made up the study cohort after excluding patients who were lost to follow-up or died before undergoing control endoscopy. Results. During the follow-up, 27 patients (40%) developed oesophageal varices. Patients with higher baseline platelet count/spleen diameter ratios (p Conclusions. The use of the platelet count/spleen diameter ratio proved to be an effective means for ruling out the presence of oesophageal varices even in the longitudinal follow-up of patients.
Vincenzo Savarino - One of the best experts on this subject based on the ideXlab platform.
-
external validation of the platelet count spleen diameter ratio for the diagnosis of esophageal varices in hepatitis c virus related cirrhosis
Digestive Diseases and Sciences, 2009Co-Authors: Adnan Agha, Eram Anwar, Kaukab Bashir, Vincenzo Savarino, Edoardo G GianniniAbstract:Background Screening for esophageal varices (EV) is an important part of the diagnostic workup of cirrhotic patients. Aims To independently validate the use of the platelet count/spleen diameter ratio for the non-invasive diagnosis of EV in patients with HCV-related cirrhosis and in a sub-group of patients with compensated disease. Methods A platelet count/spleen diameter ratio cut-off value of 909 was evaluated for the diagnosis of EV in the whole population (n = 311) and in patients with compensated disease alone (n = 114). Compensated disease was defined as the absence of ascites as detected by abdominal ultrasound in patients who are not on diuretics and absence of hepatic encephalopathy. Results In the whole cohort (EV prevalence 49.5%), the platelet count/spleen diameter ratio 909 cut-off value had 96.9% positive predictive value, 100% negative predictive value, and 98.4% efficiency for EV diagnosis. In compensated cirrhotics (EV prevalence 26.3%), the platelet count/spleen diameter ratio 909 cut-off showed an excellent negative predictive value (100%) and a positive predictive value of 93.8%. for the diagnosis of EV. Conclusions In patients with HCV-related cirrhosis, the platelet count/spleen diameter may be proposed as a non-invasive tool for EV diagnosis, especially in financially deprived developing countries.
-
application of the platelet count spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis a validation study based on follow up
Digestive and Liver Disease, 2005Co-Authors: Edoardo G Giannini, Vincenzo Savarino, Federica Botta, P Borro, Pietro Dulbecco, Emanuela Testa, C Mansi, R TestaAbstract:Abstract Background. Screening for oesophageal varices represents an important part of the diagnostic work-up of cirrhotic patients. We have previously shown that the platelet count/spleen diameter ratio is a parameter that can rule out the presence of oesophageal varices safely and in a cost-effective fashion. Aim. To evaluate the prognostic and diagnostic accuracy of the platelet count/spleen diameter ratio for ruling out the presence of oesophageal varices in the follow-up of a cohort of cirrhotic patients without oesophageal varices at inclusion. Methods. After initial endoscopy, the 106 cirrhotic patients without oesophageal varices who participated in our previous study were followed-up with annual or biannual surveillance endoscopy. Patients were censored at the time of diagnosis of oesophageal varices or at their last visit, and at that time platelet count and spleen diameter were recorded. Sixty-eight patients made up the study cohort after excluding patients who were lost to follow-up or died before undergoing control endoscopy. Results. During the follow-up, 27 patients (40%) developed oesophageal varices. Patients with higher baseline platelet count/spleen diameter ratios (p Conclusions. The use of the platelet count/spleen diameter ratio proved to be an effective means for ruling out the presence of oesophageal varices even in the longitudinal follow-up of patients.
R Testa - One of the best experts on this subject based on the ideXlab platform.
-
application of the platelet count spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis a validation study based on follow up
Digestive and Liver Disease, 2005Co-Authors: Edoardo G Giannini, Vincenzo Savarino, Federica Botta, P Borro, Pietro Dulbecco, Emanuela Testa, C Mansi, R TestaAbstract:Abstract Background. Screening for oesophageal varices represents an important part of the diagnostic work-up of cirrhotic patients. We have previously shown that the platelet count/spleen diameter ratio is a parameter that can rule out the presence of oesophageal varices safely and in a cost-effective fashion. Aim. To evaluate the prognostic and diagnostic accuracy of the platelet count/spleen diameter ratio for ruling out the presence of oesophageal varices in the follow-up of a cohort of cirrhotic patients without oesophageal varices at inclusion. Methods. After initial endoscopy, the 106 cirrhotic patients without oesophageal varices who participated in our previous study were followed-up with annual or biannual surveillance endoscopy. Patients were censored at the time of diagnosis of oesophageal varices or at their last visit, and at that time platelet count and spleen diameter were recorded. Sixty-eight patients made up the study cohort after excluding patients who were lost to follow-up or died before undergoing control endoscopy. Results. During the follow-up, 27 patients (40%) developed oesophageal varices. Patients with higher baseline platelet count/spleen diameter ratios (p Conclusions. The use of the platelet count/spleen diameter ratio proved to be an effective means for ruling out the presence of oesophageal varices even in the longitudinal follow-up of patients.
Adnan Agha - One of the best experts on this subject based on the ideXlab platform.
-
external validation of the platelet count spleen diameter ratio for the diagnosis of esophageal varices in hepatitis c virus related cirrhosis
Digestive Diseases and Sciences, 2009Co-Authors: Adnan Agha, Eram Anwar, Kaukab Bashir, Vincenzo Savarino, Edoardo G GianniniAbstract:Background Screening for esophageal varices (EV) is an important part of the diagnostic workup of cirrhotic patients. Aims To independently validate the use of the platelet count/spleen diameter ratio for the non-invasive diagnosis of EV in patients with HCV-related cirrhosis and in a sub-group of patients with compensated disease. Methods A platelet count/spleen diameter ratio cut-off value of 909 was evaluated for the diagnosis of EV in the whole population (n = 311) and in patients with compensated disease alone (n = 114). Compensated disease was defined as the absence of ascites as detected by abdominal ultrasound in patients who are not on diuretics and absence of hepatic encephalopathy. Results In the whole cohort (EV prevalence 49.5%), the platelet count/spleen diameter ratio 909 cut-off value had 96.9% positive predictive value, 100% negative predictive value, and 98.4% efficiency for EV diagnosis. In compensated cirrhotics (EV prevalence 26.3%), the platelet count/spleen diameter ratio 909 cut-off showed an excellent negative predictive value (100%) and a positive predictive value of 93.8%. for the diagnosis of EV. Conclusions In patients with HCV-related cirrhosis, the platelet count/spleen diameter may be proposed as a non-invasive tool for EV diagnosis, especially in financially deprived developing countries.
Sally W Vernon - One of the best experts on this subject based on the ideXlab platform.
-
a centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer Screening guidelines over 5 years a randomized trial
Cancer, 2017Co-Authors: Beverly B Green, Melissa L Anderson, Andrea J Cook, Jessica Chubak, Sharon Fuller, Richard T Meenan, Sally W VernonAbstract:Background Screening over many years is required to optimize reductions in colorectal cancer (CRC) mortality. However, no prior trials have compared strategies for obtaining long-term adherence. METHODS Systems of Support to Increase Colorectal Cancer Screening and Follow-Up was implemented in an integrated health care organization in Washington State. Between 2008 and 2009, 4675 individuals aged 50 to 74 years were randomized to receive the usual care (UC), which included clinic-based strategies to increase CRC Screening (arm 1), or, in years 1 and 2, mailings with a call-in number for colonoscopy and mailed fecal tests (arm 2), mailings plus brief telephone assistance (arm 3), or mailings and assistance plus nurse navigation (arm 4). Active-intervention subjects (those in arms 2, 3, and 4 combined) who were still eligible for CRC Screening were randomized to mailings being stopped or continued in years 3 and 5. The time in compliance with CRC Screening over 5 years was compared for persons assigned to any intervention and persons assigned to UC. Screening tests contributed time on the basis of national guidelines for Screening intervals (fecal tests annually, sigmoidoscopy every 5 years, and colonoscopy every 10 years). RESULTS All participants contributed data, but they were censored at disenrollment, death, the age of 76 years, or a diagnosis of CRC. Compared with UC participants, intervention participants had 31% more adjusted covered time over 5 years (incidence rate ratio, 1.31; 95% confidence interval, 1.25-1.37; covered time, 47.5% vs 62.1%). Fecal testing accounted for almost all additional covered time. CONCLUSIONS In a health care organization with clinic-based activities to increase CRC Screening, a centralized program led to increased CRC Screening adherence over 5 years. Longer term data on Screening adherence and its impact on CRC outcomes are needed. Cancer 2017. © 2017 American Cancer Society.
-
colorectal cancer test use from the 2005 national health interview survey
Cancer Epidemiology Biomarkers & Prevention, 2008Co-Authors: Jean A Shapiro, Laura C Seeff, Trevor D Thompson, Marion R Nadel, Carrie N Klabunde, Sally W VernonAbstract:Background: Screening is effective in reducing colorectal cancer mortality. Recommended colorectal cancer Screening options include a home fecal occult blood test (FOBT) or colorectal endoscopy (sigmoidoscopy or colonoscopy). Past surveys have indicated that colorectal cancer Screening prevalence in the United States is low. The purpose of this analysis was to determine the prevalence of colorectal cancer test use in the United States by various factors and to examine reasons for not having a colorectal cancer test. Methods: Data on respondents ages ≥50 years from the 2005 National Health Interview Survey ( n = 13,269) were analyzed. The proportion of the U.S. population that had home FOBT within the past year or endoscopy within the past 10 years was examined by sociodemographic, health-care access, and other health-related factors. Reported reasons for not having FOBT or endoscopy were also analyzed. Results: The age-standardized proportion of respondents who reported FOBT within the past year and/or endoscopy within the past 10 years was 50.0% [95% confidence interval (95% CI), 48.8-51.2]. Colorectal cancer testing rates were particularly low among people without health-care coverage (24.1%; 95% CI, 19.2-29.7) or without a usual source of health care (24.7%; 95% CI, 20.8-29.0). The most commonly reported reason for not having a colorectal cancer test was “never thought about it.” Conclusions: In 2005, about half of Americans ages ≥50 years did not have appropriate colorectal cancer testing. Increased efforts to expand health-care coverage or to provide colorectal cancer tests to people without health-care coverage are needed to increase colorectal cancer Screening. (Cancer Epidemiol Biomarkers Prev 2008;17(7):1623–30)
-
patterns and predictors of colorectal cancer test use in the adult u s population
Cancer, 2004Co-Authors: C Laura M D Seeff, Jean A Shapiro, Marion R Nadel, Carrie N Klabunde, Sally W Vernon, B Trevor S Thompson, Ralph J CoatesAbstract:Background Screening is effective in reducing the incidence and mortality of colorectal cancer. Rates of colorectal cancer test use continue to be low. METHODS The authors analyzed data from the National Health Interview Survey concerning the use of the home-administered fecal occult blood test (FOBT) and sigmoidoscopy/colonoscopy/proctoscopy to estimate current rates of colorectal cancer test use and to identify factors associated with the use or nonuse of tests. RESULTS In 2000, 17.1% of respondents reported undergoing a home FOBT within the past year, 33.9% reported undergoing an endoscopy within the previous 10 years, and 42.5% reported undergoing either test within the recommended time intervals. The use of colorectal cancer tests varied by gender, race, ethnicity, age, education, income, health care coverage, and having a usual source of care. Having seen a physician within the past year had the strongest association with test use. Lack of awareness and lack of physician recommendation were the most commonly reported barriers to undergoing such tests. CONCLUSIONS Less than half of the U.S. population age ≥ 50 years underwent colorectal cancer tests within the recommended time intervals. Educational initiatives for patients and providers regarding the importance of colorectal cancer Screening, efforts to reduce disparities in test use, and ensuring that all persons have access to routine primary care may help increase Screening rates. Cancer 2004. © 2004 American Cancer Society.
